In the last trading session, 1.08 million Candel Therapeutics Inc (NASDAQ:CADL) shares changed hands as the company’s beta touched -0.66. With the company’s per share price at $4.39 changed hands at -$0.45 or -9.19% during last session, the market valuation stood at $207.60M. CADL’s last price was a discount, traded about -232.57% off its 52-week high of $14.60. The share price had its 52-week low at $3.79, which suggests the last value was 13.67% up since then. When we look at Candel Therapeutics Inc’s average trading volume, we note the 10-day average is 1.31 million shares, with the 3-month average coming to 1.23 million.
Analysts gave the Candel Therapeutics Inc (CADL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CADL as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Candel Therapeutics Inc’s EPS for the current quarter is expected to be -0.24.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Instantly CADL was in red as seen at the end of in last trading. With action -21.10%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -49.37%, with the 5-day performance at -21.10% in the red. However, in the 30-day time frame, Candel Therapeutics Inc (NASDAQ:CADL) is -46.40% down. Looking at the short shares, we see there were 3.45 million shares sold at short interest cover period of 2.5 days.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -43.86%. The 2025 estimates are for Candel Therapeutics Inc earnings to increase by 13.60%, but the outlook for the next 5-year period is at 16.34% per year.
CADL Dividends
Candel Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Mar-12.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 18.54% of Candel Therapeutics Inc shares while 44.13% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 54.18%. There are 44.13% institutions holding the Candel Therapeutics Inc stock share, with NORTHPOND VENTURES, LLC the top institutional holder. As of 2024-06-30, the company held 6.477% of the shares, roughly 1.94 million CADL shares worth $12.0 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 2.8035% or 0.82 million shares worth $5.08 million as of 2024-06-30.
Among Mutual Funds, the top two as of Feb 28, 2025 were Fidelity Select Portfolios-Biotechnology Portfolio and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 5.54 shares estimated at $24.37 million under it, the former controlled 11.74% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.83% of the shares, roughly 866.65 shares worth around $3.81 million.
